Humulina Regular (Insulin Human)

Humulina Regular is indicated for the treatment of diabetes mellitus when insulin therapy is required to achieve glycemic control. It is used in both type 1 and type 2 diabetes, as well as in specific clinical situations where rapid‑acting insulin is needed.

• Type 1 diabetes mellitus: basal and mealtime insulin replacement.
• Type 2 diabetes mellitus: adjunct to oral agents when glycemic targets are not met.
• Hospitalized patients requiring intravenous insulin infusion for acute hyperglycemia.
• Gestational diabetes when other therapies are insufficient (under specialist supervision).
• Pediatric patients with type 1 diabetes, dosed according to weight and clinical response.

• Humulina Regular contains recombinant human insulin that binds to insulin receptors on cell membranes. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑kinase/Akt pathway, facilitating translocation of GLUT‑4 transporters to the plasma membrane and increasing glucose uptake in muscle and adipose tissue. Simultaneously, hepatic gluconeogenesis and glycogenolysis are suppressed, reducing endogenous glucose production and lowering blood glucose concentrations in the bloodstream.

Adverse reactions to Humulina Regular may vary in frequency and severity; they are reported in clinical use and post‑marketing surveillance.

Common

• Hypoglycemia (low blood glucose) presenting with sweating, tremor, or confusion.
• Redness, swelling, or itching at the injection site.
• Transient weight gain associated with improved glycemic control.
• Lipodystrophy, including lipohypertrophy or lipoatrophy at repeated injection sites.
• Mild allergic skin reactions such as rash or urticaria.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Anaphylactic reaction with difficulty breathing, throat swelling, or hives.
• Significant hypokalemia causing muscle weakness or cardiac arrhythmia.
• Edema or fluid retention, particularly in patients with cardiac or renal disease.
• Acute metabolic acidosis or ketoacidosis if insulin therapy is abruptly discontinued.

When prescribing Humulina Regular, clinicians consider several precautionary factors to ensure safe and effective use.

• Adjust dose in patients with renal or hepatic impairment.
• Monitor blood glucose closely during illness, stress, or changes in diet.
• Use caution in pregnant or lactating women; benefits must outweigh risks.
• Evaluate for hypoglycemia risk in elderly or those with irregular meals.
• Avoid use in patients with known hypersensitivity to human insulin or any excipients.
• Consider cardiovascular status; rapid changes in glucose may affect heart disease.

Humulina Regular may interact with other medications or substances that affect glucose metabolism, insulin sensitivity, or the clinical presentation of hypoglycemia, requiring careful management.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment.
• Beta‑blockers that mask hypoglycemia symptoms.
• MAO‑inhibitors that may potentiate insulin’s glucose‑lowering effect.
• Use of high-dose glucagon may counteract insulin effect.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) may increase hypoglycemia risk.
• Corticosteroids can raise glucose, requiring higher insulin doses.
• Thyroid hormones may alter insulin metabolism.
• Alcohol intake can cause delayed hypoglycemia.
• Loop diuretics may affect potassium levels, influencing insulin action.